Cytos Biotechnology aims to foster an innovative and creative working environment that enables its researchers to contribute cutting-edge science to the Company’s own R&D programs as well as to the scientific community. Together with their collaborators in academia and clinical centers, Cytos Biotechnology’s scientists regularly publish their R&D achievements in peer-reviewed scientific journals. 
 

• Publications relating to Immunodrug™ candidates
• Publications relating to basic and applied immunological research
• Publications relating to complementary technologies

4) Selected scientific presentations


Publications relating to preclinical and clinical Immunodrug™ candidates  

 

• Link A and Bachmann MF (2010). Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy, 2(4):561
• Uermösi C et al. (2010). Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol., 126(2):375
• Spohn G et al. (2010). A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J., 7:146
• Kündig TM and Bachmann MF (2010). Allergen-specific immunotherapy: Regulatory T cells or allergen-specific IgG? Hum Vaccine., Epub ahead of print
• Tissot AC et al. (2010). Versatile virus-like particle carrier for epitope based vaccines. PLoS One, 5(3):e9809
• Röhn TA and Bachmann MF (2010). Vaccines against non-communicable diseases. Curr Opin Immunol., 22(3):391
• Jegerlehner A et al. (2010). Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine, 28(33):5503
• Zou Y et al. (2010). Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine, 28(18:3192
• Schmitz N et al. (2009). Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med.,  206(9):1941
• Maurer P et al. (2009). Immunization against angiotensins for the treatmenf of hypertension. Clin Immunol., Epub ahead of print
• Senti G et al. (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy, 39(4):562-70
• Jennings GT and Bachmann MF (2009). Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol., 49:303-26
• Jennings GT and Bachmann MF (2008). The coming of age of virus-like particle vaccines. Biol Chem., 389(5):521-36
• Fulurija A et al (2008). Vaccination against GIP for the treatment of obesity. PLoS one, 3(9):e3163
• Cornuz J et al. (2008). A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS one, 3(6):e2547
• Manolova V et al. (2008). Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol., 38(5):1404-13
• Tissot AC et al. (2008). Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet, 371(9615):821-7
• Jennings GT and Bachmann MF (2008). The coming of age of virus-like particle vaccines. Biol Chem., March 6
• Spohn G et al. (2008). Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol., 38(3):877-87
• Spohn G and Bachmann MF (2008). Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines, 7(1):43-54
• Bessa J et al. (2008). Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol., 38(1):114-26
• Hinton HJ et al. (2008). Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol., 319:1-15
• Maurer P and Bachmann MF (2007). Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs., 16(11):1775-83
• Spohn G and Bachmann MF (2007). Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv Exp Med Biol., 602:135-42
• Spohn G et al. (2007). A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol., 178(11):7450-7
• Jennings GT and Bachmann MF (2007). Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med., 7(2):143-55
• Ambühl PM et al. (2007). A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens., 25(1):63-72
• Dyer MR et al. (2006). A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today., 11(21-22):1028-33
• Röhn TA et al. (2006). Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol., 36(11):2857-67
• Sonderegger I et al. (2006). Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol., 36(11):2849-56
• Kündig TM et al. (2006). Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol., (117(6):1470-6
• Maurer P and Bachmann MF (2006). Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther., 8(1):11-6
• Spohn G et al. (2005). Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol., 175(9):6211-8
• Maurer P et al. (2005). A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005 Jun 22
• Ruedl C et al. (2005). Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79:717-724
• Jegerlehner A et al. (2004). Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immuol 172:5598-5605
• Storni T et al. (2004). Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.
  J Immunol., 172:1777
• Bachmann MF and Dyer MR (2004). Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov., 3:81
• Spohn G and Bachmann MF (2003). Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther. 3:469
• Bachmann MF (2002). Vaccination against Alzheimer's disease: hope renewed. Trends Immunol., 23:569
• Jennings GT and Bachmann MF (2002). Immunotherapies: cause for measured optimism. Drug Discovery Today, 7:994
• Jegerlehner A et al. (2002). A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine, 20:3104
• Storni T et al. (2002). Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
  J Immunol., 168:2880
• Ruedl C et al. (2002). Cross-presentation of virus-like particles by skin-derived CD8^- DCs: A dispensable role for TAP. Eur J Immunol., 32:818
• Bachmann MF and Jennings GT (2001). Challenges and New Approaches for the Vaccine Industry. Drug Disc Today, 6:566
• Pearson S (2001). Corporate profile: Cytos builds on an immunotargeting platform. Gen. Eng. News, 21:No. 8
• Nieba L and Bachmann MF (2000). A new generation of vaccines. Mod. Asp. Immunobiol., 1:36
• Fehr T et al. (1998). T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. PNAS, 95:9477
• Bachmann MF et al. (1998). Cutting edge commentary: Immune responses in the absence of costimulation: Viruses know the trick. J Immunol., 161:5791
• Bachmann MF et al. (1993). The influence of antigen organization on B cell responsiveness. Science, 262:1448

  Publications relating to basic and applied immunological research  

• Bessa J and Bachmann MF (2010). T cell-dependent and -independent IgA responses: role of TLR signalling. Immunol Invest., 39(4-5):407
• Bessa J et al. (2010). Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intinsic manner. J Immunol., 184(9):4615
• Keller SA et al. (2010). Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immuno., 184(1):26
• Keller SA et al. (2010). Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol., 40(1):103
• Bessa J et al. (2009). Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses.J Immunol., 183(6):3788
• von Allmen CE et al. (2009). Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA, 106(28):11673
• Araki K et al. (2009). mTOR regulates memory CD8 T-cell differentiation. Nature, 460(7251):108
• Keller SA et al. (2009). Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles. J Immunol., 182(10):6261
• von Allmen CE et al. (2008). Identification of Ly-6K as a novel marker for mouse plasma cells. Mol Immunol., 45(10):2727-33
• Luckashenak N et al. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity., 28(4):521-32
• Agnellini P et al. (2008). Kinetic and mechanistic requirements for helping CD 8 T cells. J Immunol., 180(3)1517-25
• Bachmann MF and Oxenius A. (2007). Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep., 8(12):1142-8
• Bachmann MF et al. (2007). Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol., 37(6):1502-12
• Gatto D et al. (2007). Heterogeneous antibody repertoire of marginal zone B cells specific for virus-like particles. Microbes Infect., 9(3):391-9
• Boulter JM et al. (2007). Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol., 37(3):798-806
• Jegerlehner A et al. (2007). TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol., 178(4):2415-20
• Gatto D et al. (2007). Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol., 178(1):67-76
• Bachmann MF et al. (2006). Chemokines: more than just road signs. Nat Rev Immunol., 6(2):159-64
• Marsland BJ et al. (2005). Innate signals compensate for the absence of PKC-(theta) during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci USA 102(40):14374-9
• Bachmann MF et al. (2005). Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.
  J Immunol., 175(7):4686-96
• Bachmann MF et al. (2005). Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol., 175(7):4677-85
• Marsland BJ et al. (2005). CCL19 and CCL21 induce a potent pro-inflammatory differentiation program in licensed dendritic cells. Immunity 22:492
• Gatto D and Bachmann MF (2005). Function of marginal zone B cells in antiviral B-cell responses. Crit Rev Immunol. 25(4):331-42 
• Gatto D et al. (2005). Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 201:993
• Gatto D et al. (2004). Rapid response of marginal zone B cells to viral particles. J Immunol 173:4308-4316
• Sirena D et al. (2004). The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78:4454-4462
• Storni T and Bachmann MF (2004). Loading of the MHC class I and MHC class II presentation pathways by exogenous antigens: a quantitative in vivo comparison.
  J Immunol., 172:6129
• Freer G et al. (2004). Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology 322:360-369
• Bachmann MF et al. (2004). Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells.
  J Immunol 173:2217-2221
• Storni T et al. (2003). Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol., 171:795 
• Schwarz K et al. (2003). Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol, 33:1465 
• Jegerlehner A et al. (2002). Regulation of IgG antibody responses by epitope density and CD21-mediated co-stimulation. Eur J Immunol., 32:3305
• Bachmann MF and Kopf M (2002). Balancing protective immunity and immunopathology. Curr Opin Immunol., 14:413 
• Kopf M et al. (2002). Complement component C3 promotes T cell priming and lung migration to control acute influenza virus infection. Nature Med., 8:373 
• Bachmann MF (2002). TREM-2: A novel link between dendritic-cell maturation and T-cell priming. Trends in Immunol., 23:10
• Bachmann MF (2001). Blocking lymphotoxin: A potential therapy for diabetes? Trends in Immunol., 22:420
• Bachmann MF and Kopf M (2001). On the role of the innate immunity in autoimmune disease. J Exp Med., 193:1393
• Bachmann MF (2001). Complements for mad cow disease. Trends in Immunol., 22:297
• Kündig TM et al. (1998). Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity, 5:41
• Bachmann MF et al. (1997). The role of antibody concentration and avidity in antiviral protection. Science, 276:2024

  Publications relating to complementary technologies     

• Beerli RR et al (2009). Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenz A M2 protein. Virol J, 21;6:224
• Beerli RR et al (2008). Isolation of human monoclonal antibodies by mammalian cell display. PNAS., 23;105(38):14336-41
• Von Allmen CE et al. (2008). Identification of Ly-6K as a novel marker for mouse plasma cells. Mol Immunol., 45(10):2727-33
• Gründemann C et al. (2006). Cutting edge: identification of e-cadherin as a ligand for the murine killer cell lectin-like receptor g1. J Immunol., 176;176(3):1311-5
• Ivanova L et al. (2005). Hybrid Sindbis/Epstein-Barr virus episomal expression vector for inducible production of proteins. Biotechniques 39(2):209-12
• Bättig P et al. (2004). Enhanced apoptotic activity of a structurally optimized form of galectin-1. Mol Immunol 41:9-18 
• Ruedl C et al. (2004). Rapid functional cloning of cell adhesion molecules. Biotechniques 37:912, 914, 916
• Boorsma M et al. (2003). Alphavirus cDNA based expression vectors: Effects of RNA transcription and nuclear export. Biotechnol Bioeng., 81:553
• Boorsma M et al. (2002). Bioprocess applications of a Sindbis virus-based temperature-inducible expression system. Biotechnol Bioeng., 79:602 
• Koller D et al. (2001). A high-throughput alphavirus-based expression cloning system for mammalian cells. Nature Biotech., 19:851
• Boorsma M and Bachmann MF (2001). New applications of alphavirus-based expression vectors. Cytotechnology, 35:203
• Blaser C et al. (2000). Drug Discovery: One-step identification of both drug & target.
  Gen. Eng. News, 20:No. 6
• Blaser C et al. (2000). Novel technologies for functional genomics and antibody mediated therapies. Chimia, 54:165
• Koller D and Bachmann MF (2000). Functional Expression Cloning – Tools to accelerate the identification of gene function. Europ. Biopharm. Review, June 2000
• Boorsma M et al. (2000). A temperature-regulated replicon-based DNA expression system. Nature Biotech., 18:429

Selected scientific presentations (add two)